由于制造商供应协议有限,拉丁美洲国家错过了廉价艾滋病毒药物。 Latin American countries miss out on cheaper HIV drug due to manufacturer's limited supply agreement.

多数拉丁美洲国家将无法获得廉价的艾滋病毒药物Lenacapavir。 Most Latin American countries won't have access to a cheaper version of the HIV drug lenacapavir. 制药商Gilead Science只同意向少数国家(主要是非洲和亚洲国家)提供成本较低的版本,由于制造成本较高,绕过较大的拉丁美洲国家。 The drugmaker Gilead Sciences has only agreed to supply the lower-cost version to a limited number of countries, mostly in Africa and Asia, bypassing larger Latin American nations due to higher manufacturing costs. 这种排除可能限制这些地区艾滋病毒患者的治疗选择。 This exclusion could limit treatment options for HIV patients in those regions.